-
Something wrong with this record ?
HIV disease metrics and COVID-19 infection severity and outcomes in people living with HIV in central and eastern Europe
C. Oprea, S. Quirke, I. Ianache, D. Bursa, S. Antoniak, N. Bogdanic, AI. Vassilenko, K. Aimla, R. Matulionyte, N. Rukhadze, A. Harxhi, L. Fleischhans, B. Lakatos, D. Sedlacek, G. Dragovic, A. Verhaz, N. Yancheva, O. Acet, K. Protopapas, JD....
Language English Country England, Great Britain
Document type Observational Study, Journal Article
PubMed
38014768
DOI
10.1111/hiv.13578
Knihovny.cz E-resources
- MeSH
- COVID-19 * epidemiology complications MeSH
- HIV Infections * complications drug therapy epidemiology MeSH
- Humans MeSH
- CD4 Lymphocyte Count MeSH
- Respiratory Insufficiency * MeSH
- Retrospective Studies MeSH
- SARS-CoV-2 MeSH
- COVID-19 Testing MeSH
- Viral Load MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Geographicals
- Europe, Eastern MeSH
BACKGROUND: To date there remains much ambiguity in the literature regarding the immunological interplay between SARS-CoV-2 and HIV and the true risk posed to coinfected individuals. There has been little conclusive data regarding the use of CD4 cell count and HIV viral load stratification as predictors of COVID-19 severity in this cohort. METHODS: We performed a retrospective, observational cohort study on people living with HIV (PLWH) who contracted COVID-19 in central and eastern Europe. We enrolled 536 patients from 16 countries using an online survey. We evaluated patient demographics, HIV characteristics and COVID-19 presentation and outcomes. Statistical analysis was performed using SPSS 20.1. RESULTS: The majority of the study cohort were male (76.4%) and 152 (28.3%) had a significant medical comorbidity. Median CD4 cell count at COVID-19 diagnosis was 605 cells/μL [interquartile range (IQR) 409-824]. The majority of patients on antiretroviral therapy (ART) were virally suppressed (92%). In univariate analysis, CD4 cell count <350 cells/μL was associated with higher rates of hospitalization (p < 0.0001) and respiratory failure (p < 0.0001). Univariate and multivariate analyses found that an undetectable HIV VL was associated with a lower rate of hospitalization (p < 0.0001), respiratory failure (p < 0.0001), ICU admission or death (p < 0.0001), and with a higher chance of full recovery (p < 0.0001). CONCLUSION: We can conclude that detectable HIV viral load was an independent risk factor for severe COVID-19 illness and can be used as a prognostic indicator in this cohort.
Carol Davila University for Medicine and Pharmacy Bucharest Romania
Charles University Faculty of Medicine in Plzeň University Hospital Plzeň Plzen Czech Republic
Department of Adults' Infectious Diseases Medical University of Warsaw Warsaw Poland
Department of Medicine Galway University Hospital Galway Ireland
Infectious Diseases AIDS and Clinical Immunology Center Tbilisi Georgia
Tartu University Hospital Tartu Estonia
University Hospital Center of Tirana Infectious Disease Service Tirana Albania
University Hospital for Infectious Diseases University of Zagreb School of Medicine Zagreb Croatia
Victor Babes Clinical Hospital for Infectious and Tropical Diseases Bucharest Romania
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006973
- 003
- CZ-PrNML
- 005
- 20240423155622.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/hiv.13578 $2 doi
- 035 __
- $a (PubMed)38014768
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Oprea, Cristiana $u Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania $u Carol Davila University for Medicine and Pharmacy, Bucharest, Romania $1 https://orcid.org/0000000195812527
- 245 10
- $a HIV disease metrics and COVID-19 infection severity and outcomes in people living with HIV in central and eastern Europe / $c C. Oprea, S. Quirke, I. Ianache, D. Bursa, S. Antoniak, N. Bogdanic, AI. Vassilenko, K. Aimla, R. Matulionyte, N. Rukhadze, A. Harxhi, L. Fleischhans, B. Lakatos, D. Sedlacek, G. Dragovic, A. Verhaz, N. Yancheva, O. Acet, K. Protopapas, JD. Kowalska, Euroguidelines in Central and Eastern Europe Network Group
- 520 9_
- $a BACKGROUND: To date there remains much ambiguity in the literature regarding the immunological interplay between SARS-CoV-2 and HIV and the true risk posed to coinfected individuals. There has been little conclusive data regarding the use of CD4 cell count and HIV viral load stratification as predictors of COVID-19 severity in this cohort. METHODS: We performed a retrospective, observational cohort study on people living with HIV (PLWH) who contracted COVID-19 in central and eastern Europe. We enrolled 536 patients from 16 countries using an online survey. We evaluated patient demographics, HIV characteristics and COVID-19 presentation and outcomes. Statistical analysis was performed using SPSS 20.1. RESULTS: The majority of the study cohort were male (76.4%) and 152 (28.3%) had a significant medical comorbidity. Median CD4 cell count at COVID-19 diagnosis was 605 cells/μL [interquartile range (IQR) 409-824]. The majority of patients on antiretroviral therapy (ART) were virally suppressed (92%). In univariate analysis, CD4 cell count <350 cells/μL was associated with higher rates of hospitalization (p < 0.0001) and respiratory failure (p < 0.0001). Univariate and multivariate analyses found that an undetectable HIV VL was associated with a lower rate of hospitalization (p < 0.0001), respiratory failure (p < 0.0001), ICU admission or death (p < 0.0001), and with a higher chance of full recovery (p < 0.0001). CONCLUSION: We can conclude that detectable HIV viral load was an independent risk factor for severe COVID-19 illness and can be used as a prognostic indicator in this cohort.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a HIV infekce $x komplikace $x farmakoterapie $x epidemiologie $7 D015658
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a testování na COVID-19 $7 D000086742
- 650 12
- $a COVID-19 $x epidemiologie $x komplikace $7 D000086382
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 _2
- $a počet CD4 lymfocytů $7 D018791
- 650 12
- $a respirační insuficience $7 D012131
- 650 _2
- $a virová nálož $7 D019562
- 651 _2
- $a východní Evropa $7 D005061
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Quirke, Siobhan $u Department of Medicine, Galway University Hospital, Galway, Ireland $1 https://orcid.org/000000031260615X
- 700 1_
- $a Ianache, Irina $u Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania $u Carol Davila University for Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Bursa, Dominik $u Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000152891974
- 700 1_
- $a Antoniak, Sergii $u Viral Hepatitis and AIDS Department, Gromashevsky Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine
- 700 1_
- $a Bogdanic, Nikolina $u University Hospital for Infectious Diseases, University of Zagreb, School of Medicine, Zagreb, Croatia
- 700 1_
- $a Vassilenko, Anne I $u Global Fund Grant Management Department, Republican Scientific and Practical Center for Medical Technologies, Minsk, Belarus
- 700 1_
- $a Aimla, Kersti $u Tartu University Hospital, Tartu, Estonia
- 700 1_
- $a Matulionyte, Raimonda $u Vilnius University, Faculty of Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- 700 1_
- $a Rukhadze, Nino $u Infectious Diseases, AIDS and Clinical Immunology Center, Tbilisi, Georgia
- 700 1_
- $a Harxhi, Arjan $u University Hospital Center of Tirana, Infectious Disease Service, Tirana, Albania
- 700 1_
- $a Fleischhans, Lukáš $u Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Faculty Hospital Bulovka Hospital, Prague, Czech Republic
- 700 1_
- $a Lakatos, Botond $u National Institute of Hematology and Infectious Diseases, South-Pest Central Hospital, National Center of HIV, Budapest, Hungary
- 700 1_
- $a Sedlacek, Dalibor $u Charles University, Faculty of Medicine in Plzeň, University Hospital Plzeň, Plzen, Czech Republic
- 700 1_
- $a Dragovic, Gordana $u Faculty of Medicine, University of Belgrade, Department of Pharmacology, Clinical Pharmacology and Toxicology, Belgrade, Serbia
- 700 1_
- $a Verhaz, Antonija $u Department for Infectious Diseases, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
- 700 1_
- $a Yancheva, Nina $u Department for AIDS, Specialized Hospital for Active Treatment of Infectious and Parasitic Disease Sofia, Sofi, Bulgaria
- 700 1_
- $a Acet, Oguzhan $u Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, Izmir, Turkey
- 700 1_
- $a Protopapas, Konstantinos $u University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Kowalska, Justyna Dominika $u Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000311664462
- 710 2_
- $a Euroguidelines in Central and Eastern Europe Network Group
- 773 0_
- $w MED00007240 $t HIV medicine $x 1468-1293 $g Roč. 25, č. 3 (2024), s. 343-352
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38014768 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155618 $b ABA008
- 999 __
- $a ok $b bmc $g 2081138 $s 1216740
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 25 $c 3 $d 343-352 $e 20231128 $i 1468-1293 $m HIV medicine $n HIV Med $x MED00007240
- LZP __
- $a Pubmed-20240412
